(By David Ranii, (Raleigh) News & Observer) The firestorm over the safety of GlaxoSmithKline's diabetes drug Avandia could hurt profit at one of the Triangle's largest employers, weigh on its stock and provide new ammunition for lawsuits.A Senate committee report released over the weekend contends that GSK knew about heart attack risks linked to Avandia years before the evidence became public.